Form 8-K - Current report:
SEC Accession No. 0001193125-21-046513
Filing Date
2021-02-17
Accepted
2021-02-17 16:16:11
Documents
6
Period of Report
2021-02-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d138536d8k.htm 8-K 23844
2 EX-1.1 d138536dex11.htm EX-1.1 175538
3 EX-5.1 d138536dex51.htm EX-5.1 7606
4 EX-99.1 d138536dex991.htm EX-99.1 7958
5 EX-99.2 d138536dex992.htm EX-99.2 8212
6 GRAPHIC g138536g0215232140172.jpg GRAPHIC 2785
  Complete submission text file 0001193125-21-046513.txt   228372
Mailing Address 421 KIPLING STREET PALO ALTO CA 94301
Business Address 421 KIPLING STREET PALO ALTO CA 94301 (650) 391-9740
BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38959 | Film No.: 21644967
SIC: 2834 Pharmaceutical Preparations